Reply

A.L.		Claudy
V.		Lévigne
S.		Boucheron

Department of Dermatology, Hôpital Nord, CHU St-Etienne, France

Prof. A.L. Claudy/Dr. V. Lévigne/Prof. S. Boucheron, Department of Dermatology, Hôpital Nord. CHU St-Etienne, F-42277 St-Priest-en-Jarez (France)

We read with interest the comments of the higher concentrations of the drug were Dr. Schallreuter and Dr. Ring concerning our delivered near the point of entry. However, recent article [Dermatology 1992;185:70–72]. no causes for deoxygenated venous blood Since this report, we have collected a third (e.g. chronic obstructive pulmonary disease similar case. We have treated so far more or heavy smoking) have been suspected in than 30 melanoma patients with fotemustine our cases. Therefore, we have no sufficient and such an unusual hyperpigmentation reasons to support the hypothesis of depletion of the thioredoxin pool that would activate tyrosinase and subsequently cause occurred in only 3 of them. None of our hyperpigmentation. agree that, according to our patients has been treated by local injections of high concentrations of the drug. We do infusion time,

© 1992 Karger AG, Basel

1018–8665/92/1851–0077

\$2.75/0